WHO European Region · country profile

HIV, PrEP and sexual health access in Switzerland

Name: HIV medicine, PrEP and sexual health access in Switzerland
Creator: SHAPE

Switzerland: 88% of verified HIV medicine records are reimbursed; PrEP is available but not reimbursed; sexuality education is classified as progressive. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 02/11/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

HIV medicines88% reimbursed28 of 32 verified records PrEPAvailable, not reimbursed6,968 PrEP recipients (2024; UNAIDS GAM)DoxyPEPAvailable, not reimbursedNational access and guidance Sexuality educationProgressivePolicy framework Family planning & abortionRestrictedAbortion law and contraception Migrant healthcare accessWarningEntitlement and practice

6 HIV medicine records for Switzerland are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in Switzerland?

Of 32 verified HIV medicine records for Switzerland, 28 are available and reimbursed (88%), 2 are available but not reimbursed and 2 are not available. 6 further records are still under review.

Reimbursed 28

Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Emtriva, Eviplera, Generic TDF/FTC (Emtricitabine/Tenofovir DF), Genvoya, Intelence, Isentress, Juluca, Kaletra and 14 more

Available, not reimbursed 2

Rukobia, Sunlenca

Not available 2

Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz)

See every medicine with its source ↓

Is PrEP available and reimbursed in Switzerland?

PrEP is available in Switzerland, but SHAPE's review did not find it reimbursed.

PrEP recipients: 6,968 PrEP recipients (2024; UNAIDS GAM)

UNAIDS GAM 2025 reports 6,968 people receiving PrEP in 2024. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in Switzerland?

DoxyPEP can be accessed in Switzerland, but SHAPE's review did not find it reimbursed.

Switzerland's Federal Commission for Questions relating to Sexually Transmitted Infections recommends offering DoxyPEP through shared decision-making to men who have sex with men and transgender women who have condomless sex with changing partners and had at least one bacterial STI in the previous 12 months. Use is off-label, and users must pay the costs themselves. [Source: https://www.bag.admin.ch/dam/de/sd-web/Fm8xd0NPQkUa/260319_EKSI_DOXYPEP_DE_fin_PUB.pdf]

What is the policy on sexuality education in Switzerland?

SHAPE classifies the sexuality education framework in Switzerland as progressive. This describes the national policy framework, not how every school delivers it.

National framework: Sexuality and health topics are required through cantonal curricula, but implementation, lesson time and external support differ among cantons.
Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in Switzerland?

SHAPE classifies family planning and abortion rights in Switzerland as restricted, combining abortion law and contraception policy.

Abortion: Abortion is available on request through 12 weeks under the statutory distress framework; compulsory insurance covers care subject to ordinary cost sharing.
Contraception: EPF's 2026 contraception-policy score is 55.9%; the atlas records no national coverage recorded.
Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/countries/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf]

Can migrants access healthcare in Switzerland?

SHAPE's editorial comparison places migrant healthcare access in Switzerland in the middle category (Warning). Entitlement: Mandatory insurance with emergency and necessary-care duties.

Provider type: Mandatory private insurance / cantonal services / NGO · International migrants (2024): 2,773,840

Access rule: Health insurance is mandatory in principle, including for undocumented residents, and emergency providers must deliver necessary treatment.
Main barriers: Premiums, enrolment, debt, fear of disclosure and cantonal practice can prevent effective access despite the formal framework.
Migration measure: UN DESA estimates 2,773,840 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Germany (13.4%), Italy (9.9%), Portugal (7.3%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 69.4%; Late HIV Diagnosis (CD4 <350, 2024): 54.1%

How Switzerland compares

Switzerland ranks #10 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (88%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

Italy92%Germany92%France95%Austria85%

All HIV medicines in Switzerland

Medicine	Active ingredient	Class	Status	Evidence and source	Checked
Biktarvy Gilead Sciences	Bictegravir / Emtricitabine / TAF	INSTI + NRTI/NtRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Celsentri ViiV Healthcare	Maraviroc	Entry Inhibitor	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Delstrigo Merck	Doravirine / Lamivudine / Tenofovir DF	NNRTI + NRTI/NtRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Descovy Gilead Sciences	Emtricitabine / TAF	NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Dovato ViiV Healthcare	Dolutegravir / Lamivudine	INSTI + NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Edurant Janssen	Rilpivirine	NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Emtriva Gilead Sciences	Emtricitabine	NRTI	Reimbursed	Listed on the official national reimbursement list (BAG Spezialitaetenliste, queried 2026-11-02). Details: Kaps 200 mg 30 Stk, CHF 181.54 ex-factory / 213.85 public, Selbstbehalt 10%, GTIN 7680568800033. Source: https://sl.bag.admin.ch/sl. Verified 2026-11-02.	02/11/2026
Eviplera Gilead Sciences	Rilpivirine / Emtricitabine / Tenofovir DF	NNRTI + NRTI/NtRTI	Reimbursed	Listed on the official national reimbursement list (BAG Spezialitaetenliste, queried 2026-11-02). Details: Filmtabl 30 Stk CHF 760.30 / 843.30, Selbstbehalt 10%, GTIN 7680621550011. Source: https://sl.bag.admin.ch/sl. Verified 2026-11-02.	02/11/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Multiple (Generics)	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Generic combinations are widely accessible and reimbursed under standard national health policies. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Genvoya Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / TAF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Intelence Janssen	Etravirine	NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Isentress Merck	Raltegravir	INSTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Juluca ViiV Healthcare	Dolutegravir / Rilpivirine	INSTI + NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Kaletra AbbVie	Lopinavir / Ritonavir	PI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Kivexa ViiV Healthcare	Abacavir / Lamivudine	NRTI	Reimbursed	Listed on the official national reimbursement list (BAG Spezialitaetenliste, queried 2026-11-02). Details: Filmtabl 600/300 mg 30 Stk, CHF 273.20 / 311.00, Selbstbehalt 10%, GTIN 7680569770021. Source: https://sl.bag.admin.ch/sl. Verified 2026-11-02.	02/11/2026
Odefsey Gilead Sciences	Rilpivirine / Emtricitabine / TAF	NNRTI + NRTI/NtRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Pifeltro Merck	Doravirine	NNRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Prezista Janssen	Darunavir	PI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Rekambys Janssen	Rilpivirine	Long-Acting NNRTI	Reimbursed	Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Switzerland record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys]	14/09/2026
Retrovir ViiV Healthcare	Zidovudine	NRTI	Reimbursed	Listed on the official national reimbursement list (BAG Spezialitaetenliste, queried 2026-11-02). Details: listed as "Retrovir AZT": Kaps 250 mg 40 Stk CHF 124.26 / 151.55; Sirup 200 ml CHF 25.38 / 44.00; Selbstbehalt 10%. Source: https://sl.bag.admin.ch/sl. Verified 2026-11-02.	02/11/2026
Symtuza Janssen	Darunavir / Cobicistat / Emtricitabine / TAF	PI + NRTI/NtRTI + pharmacokinetic enhancer	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Tivicay ViiV Healthcare	Dolutegravir	INSTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Triumeq ViiV Healthcare	Dolutegravir / Abacavir / Lamivudine	INSTI + NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Truvada Gilead Sciences	Emtricitabine / Tenofovir DF	NRTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Viread Gilead Sciences	Tenofovir DF	NtRTI	Reimbursed	Listed on the official national reimbursement list (BAG Spezialitaetenliste, queried 2026-11-02). Details: Filmtabl 245 mg 30 Stk, CHF 445.73 / 486.90, Selbstbehalt 40%, GTIN 7680562510020. Source: https://sl.bag.admin.ch/sl. Verified 2026-11-02.	02/11/2026
Vocabria ViiV Healthcare	Cabotegravir	INSTI	Reimbursed	Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Vocabria / Rekambys ViiV Healthcare / Janssen	Cabotegravir / Rilpivirine	Long-Acting ART	Reimbursed	EMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Ziagen ViiV Healthcare	Abacavir	NRTI	Reimbursed	Listed on the official national reimbursement list (BAG Spezialitaetenliste, queried 2026-11-02). Details: Tabl 300 mg 60 Stk CHF 199.02 / 232.85; Trink Los 240 ml CHF 56.91 / 78.30; Selbstbehalt 10%. Source: https://sl.bag.admin.ch/sl. Verified 2026-11-02.	02/11/2026
Rukobia ViiV Healthcare	Fostemsavir	Attachment Inhibitor	Available, not reimbursed	Approved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Sunlenca Gilead Sciences	Lenacapavir	Capsid Inhibitor	Available, not reimbursed	Approved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics)	Tenofovir DF / Lamivudine / Dolutegravir	INSTI + NRTI/NtRTI	Not available	Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics)	Tenofovir DF / Lamivudine / Efavirenz	NNRTI + NRTI/NtRTI	Not available	Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports]	14/09/2026
Apretude ViiV Healthcare	Cabotegravir (PrEP)	INSTI (Long-Acting PrEP)	Under review	Long-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis. The EU/EEA-wide marketing authorisation of 19 September 2023 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude]	14/09/2026
Epivir ViiV Healthcare	Lamivudine	NRTI	Under review	Lamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Switzerland. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir]	14/09/2026
Norvir AbbVie	Ritonavir	PI + pharmacokinetic enhancer	Under review	Ritonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Switzerland. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir]	14/09/2026
Rezolsta Janssen	Darunavir / Cobicistat	PI + pharmacokinetic enhancer	Under review	A fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Switzerland. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta]	14/09/2026
Stribild Gilead Sciences	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF	INSTI + NRTI/NtRTI + pharmacokinetic enhancer	Under review	A once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Switzerland. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild]	14/09/2026
Yeytuo Gilead Sciences	Lenacapavir (PrEP)	Capsid Inhibitor (Long-Acting PrEP)	Under review	Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The EU/EEA-wide marketing authorisation of 26 August 2025 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. An identical product, Lenacapavir Gilead, received a positive EMA opinion under the EU-M4all procedure for use outside the EU. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]	14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

aidsinfo.unaids.org https://aidsinfo.unaids.org/dataset
bag.admin.ch https://www.bag.admin.ch/dam/de/sd-web/Fm8xd0NPQkUa/260319_EKSI_DOXY…
unesco.org https://www.unesco.org/gem-report/en/peer
who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
abortion-policies.srhr.org https://abortion-policies.srhr.org/countries/
epfweb.org https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_20…
who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/apretude
sl.bag.admin.ch https://sl.bag.admin.ch/sl.
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/epivir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/norvir
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/stribild
ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo

Explore more

HIV medicine map PrEP and DoxyPEP map Reproductive autonomy map Health equity dashboard All countries

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.